<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28962192</article-id><article-id pub-id-type="pmc">5609215</article-id><article-id pub-id-type="doi">10.3892/etm.2017.4825</article-id><article-id pub-id-type="publisher-id">ETM-0-0-4825</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Clinical significance of mechanical ventilation on ischemic-reperfusion injury caused by lung chest trauma and VEGF expression levels in peripheral blood</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Zhong-Yi</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-4825"/><xref rid="fn1-etm-0-0-4825" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Hong-Gang</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-4825"/><xref rid="fn1-etm-0-0-4825" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>De-Qing</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-4825"/><xref rid="fn1-etm-0-0-4825" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Li-Min</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-4825"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Peng-Zhi</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-4825"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Dong-Bin</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-4825"/><xref rid="c1-etm-0-0-4825" ref-type="corresp"/></contrib></contrib-group><aff id="af1-etm-0-0-4825">Department of Cardiothoracic Surgery, Tianjin Hospital, Tianjin 300210, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-4825"><italic>Correspondence to</italic>: Dr Dong-Bin Wang, Department of Cardiothoracic Surgery, Tianjin Hospital, 406 South Jiefang Road, Tianjin 300210, P.R. China, E-mail: <email>wf8i16@163.com</email></corresp><fn id="fn1-etm-0-0-4825"><label>*</label><p>Contributed equally</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>20</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>7</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>14</volume><issue>3</issue><fpage>2531</fpage><lpage>2535</lpage><history><date date-type="received"><day>21</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>09</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Sun et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>We investigated the clinical significance of mechanical ventilation on ischemic-reperfusion injury caused by lung chest trauma as well as vascular endothelial growth factor (VEGF) expression levels in peripheral blood. Sixty-eight patients with severe chest trauma complicated with acute respiratory distress syndrome that were treated at our Tianjin Hospital from September 2013 to July 2016 were recruited. These patients were randomly and evenly divided into two groups, the research group and the control group. Thirty-four age and gender matched healthy people were selected as the normal group. Routine treatment was given to both the research and control groups, but mechanical ventilation was used in the research group. We detected pulmonary vascular resistance (PVR) and alveolar-arterial oxygen difference (AaDO<sub>2</sub>) for patients in both groups before treatment, and after treatment for 1, 3, 6 and 12 h. We also tested PMN, superoxide dismutase (SOD), malondialdehyde (MDA), NO and Ang II value 30 min before and after treatment. We used the ELISA-test to detect VEGF expression levels in peripheral blood, followed by a statistical analysis. PVR levels of different time points in the research group were significantly lower than control group after treatment. The AaDO<sub>2</sub> value of the control group is much smaller than research group (P&#x0003c;0.5) after treatment for 1, 3 or 6 h. PMN count difference and MDA level in the research group is significantly lower than the control group after treatment for 30 min, but SOD and NO levels are much higher. Ang II levels of the research group in left atrial blood is significantly lower than control group (P&#x0003c;0.05). By comparing the hospitalization times, we found that patients in the research group have a shorter duration in hospital than the control group; differences are statistically significant (P&#x0003c;0.05). Additionally, compared to control group, research group VEGF expression levels in peripheral blood are significantly lower (P&#x0003c;0.05). Therefore, mechanical ventilation can reduce the high VEGF expression levels in serum caused by ischemic-reperfusion and can be used for clinical application.</p></abstract><kwd-group><kwd>chest trauma</kwd><kwd>mechanical ventilation</kwd><kwd>vascular endothelial growth factor</kwd><kwd>lung ischemic-reperfusion injury</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Severe chest trauma is a disease with acute onset, rapid development and is often associated with acute respiratory distress syndrome (ARDS). The mortality of this disease is extremely high without a timely treatment, and can be between 50 and 70% (<xref rid="b1-etm-0-0-4825" ref-type="bibr">1</xref>). Therefore, an effective treatment for severe chest trauma patients can not only improve prognosis to enhance survival, but also reduce the occurrence of chain reaction after severe chest injury (<xref rid="b2-etm-0-0-4825" ref-type="bibr">2</xref>,<xref rid="b3-etm-0-0-4825" ref-type="bibr">3</xref>).</p><p>A causality has been found between lung ischemic-reperfusion injury and inflammatory response in various complications caused by chest trauma. Some severe cases can develop into respiratory distress syndrome, which will affect the patients' perioperative life seriously. Previous studies have found that lung ischemic preconditioning can significantly improve postoperative PaO<sub>2</sub> levels and remarkably reduce pulmonary artery pressure, lung wet/dry ratio and malondialdehyde levels, which may to some extent prevent the damage of lung tissue (<xref rid="b4-etm-0-0-4825" ref-type="bibr">4</xref>).</p><p>Previous studies report that ischemia-reperfusion injury can cause an increase in levels of blood neutrophils (PMN), peripheral blood superoxide dismutase and malondialdehyde (SOD and MDA), NO and Ang II, which probably related to ischemia, hypoxia and the stress of hypoxia of the lung (<xref rid="b5-etm-0-0-4825" ref-type="bibr">5</xref>&#x02013;<xref rid="b7-etm-0-0-4825" ref-type="bibr">7</xref>). Additionally, vascular endothelial growth factor (VEGF) can induce various physiological and pathological processes. Its expression levels can be improved markedly in angiogenesis, vascular proliferation, tissue ischemia and hypoxia conditions to meet the needs of aerobic metabolism for injury tissue, which plays an important role in tissue reconstruction. Therefore, some scholars consider that VEGF expression levels can be monitored as one of the serological index of lung ischemia-reperfusion (<xref rid="b8-etm-0-0-4825" ref-type="bibr">8</xref>). On the basis of previous studies, our study investigated the effects of mechanical ventilation on ischemic-reperfusion injury caused by lung chest trauma and VEGF expression levels in peripheral blood.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Sample selection</title><p>Sixty-eight patients with severe chest trauma complicated with ARDS who were treated at our hospital from September 2013 to July 2016 were recruited. These patients were randomly and evenly divided into two groups, the research group and the control group. The control group included 19 males and 15 females, aged 19&#x02013;72 years, average 45.3&#x000b1;12.5 years, 14 injury cases resulting from traffic accidents, 7 cases of fall, 6 cases of crush injury, 5 bluntly attack injury cases and other 2 cases; 7 cases were single chest trauma and 27 cases were multiple or compound injury. The research group included 18 males and 16 females, aged 20&#x02013;64 years (44&#x000b1;2.51); 16 injury cases due to traffic accidents, 6 fall injury cases, 7 crush injury cases, 4 bluntly attack injury cases and 1 other case; 8 cases were single chest trauma, and 26 cases were multiple or compound injury. The 34 cases in the control group were treated in Tianjin Hospital's Physical and Examination Center simultaneously. No significant differences of clinical data were found between these two groups (P&#x0003e;0.05), and they are comparable. This study was approved by the Medical Ethics Committee of Tianjin Hospital and written informed consent was obtained from the patients.</p></sec><sec><title>Inclusion and exclusion criteria</title><p>Inclusion criteria: i) NYHA cardiac function class II&#x02013;III; and ii) diagnosis of chest trauma in patients by clinical symptoms, signs, medical history, laboratories and control laboratories.</p><p>Exclusion criteria: i) patients with comprehensive symptoms of pneumothorax, severe arrhythmia and myocardial; ii) patients with cardiac pulmonary edema caused by respiratory distress and patients with non-completed clinical data; and iii) patients with mental illness or disturbance of consciousness.</p></sec><sec><title>Diagnostic criteria</title><p>All patients chosen in our study have significant traumatic injuries and acute onset. The clinical symptoms are faster respiratory rates (RR, &#x0003e;28 times/min), and pulmonary artery wedge pressure (PAWP, &#x02264;18 mmHg), the symptoms still not being able to ease after a general oxygen therapy, and a cloudy shadow was found in patients' lung by using physical and chemical inspection and X-ray examination.</p></sec><sec><title>Methods</title><p>We closely monitored the patient vital signs and established a venous channel after they were hospitalized. We administered routine treatment to these two groups of patients according to parameters such as oxygen uptake, respiratory stimulant, anti-infection, bronchiectasis, correct water electrolyte and acid-base imbalance, and nutritional support. Apart from the routine treatment, mechanical ventilation was used in the research group. The BIPAP ventilator (manufactured by Philips Respironics, Inc., Murrysville, PA, USA) was used to help patients breathe, set up S/T model for 16 times/min respiratory rate, 8 cm/H<sub>2</sub>O oxygen pressure, 4 cm/H<sub>2</sub>O EPAP, and 35&#x02013;60% oxygen concentration.</p></sec><sec><title>Observation targets</title><p>We observed the research and control group blood gas analysis before treatment and after treatment including PaCO<sub>2</sub>, PaO<sub>2</sub> and SaO<sub>2</sub>. We monitored patient lung function after treatment including MVV, FVC, and FEV0.3.</p></sec><sec><title>ELISA method to detect VEGF in peripheral blood</title><p>Peripheral venous blood was centrifuged for 5 min, and ELISA detection kits (Nanjing Jiancheng Technology Co., Ltd., Nanjing, China) were used to detect VEGF, PMN, SOD, MDA, Ang II and NO levels in peripheral blood. Refer to standardized specifications in the detection kits for test methods and procedures.</p></sec><sec><title>SOD, MDA, NO, Ang II level test</title><p>SOD is detected by xanthine oxidase, and MDA levels are detected by thiobarbituric acid method; nitric acid reductase method is used to detect NO levels. Ang II is detected by radioimmunoassay.</p></sec><sec><title>Statistical analysis</title><p>SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) is used for statistical analysis. ANOVA, t-test and &#x003c7;<sup>2</sup> test were used for qualitative data analysis, and Fisher's exact to analyze a fourfold table for patients who do not meet the criteria. In order to compare the qualitative data, the ANOVA test is used and P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Clinical settings of investigated patients</title><p>Statistical analysis of clinical settings for 68 chest trauma patients (<xref rid="tI-etm-0-0-4825" ref-type="table">Table I</xref>) indicated that there were no significant (P&#x0003e;0.05) statistical differences in gender ratio, average age, hospitalization time and BMI between different groups of patients.</p></sec><sec><title>Pulmonary vascular resistance (PVR) comparison</title><p>Both the research group (RG) and control group (CG) showed high PVR levels before treatment but no significant statistical differences (P&#x0003e;0.05). After treatment, PVR levels in both RG and CG dropped remarkably at different treatment time points (P&#x0003c;0.01). There were no significant statistic differences found between these two groups (P&#x0003e;0.05). Twelve hours after treatment, PVR levels in these two groups gradually stabilized, shown in <xref rid="tII-etm-0-0-4825" ref-type="table">Table II</xref>.</p></sec><sec><title>Comparison of peripheral blood PMN, SOD, MDA, Ang II and NO level between 30 min before and after treatment</title><p>As shown in <xref rid="tIII-etm-0-0-4825" ref-type="table">Table III</xref>, 30 min after treatment, the neutrophil numbers in peripheral blood was remarkably higher than before treatment; differences were statistically significant (P&#x0003c;0.05). However, comparison between RG and CG showed that no statistically significant differences were found (P&#x0003e;0.05). After treatment, the difference in RG was significantly smaller than CG (P&#x0003c;0.05). Thirty minutes after treatment, SOD and NO level in RG were significantly higher but the MDA levels were remarkably lower when compared to those in CG; the difference was statistically significant (P&#x0003c;0.05). Left atrial ejection (LAE) Ang II levels were also much higher (P&#x0003c;0.05); no significant difference was found between these two groups (P&#x0003e;0.05).</p></sec><sec><title>Blood gas index and lung function comparison between before treatment and after treatment</title><p>Before treatment, there were no significant differences found in PaCO<sub>2</sub>, PaO<sub>2</sub> and SaO<sub>2</sub> levels between the RG and CG group (P&#x0003e;0.05). After treatment, PaCO<sub>2</sub>, PaO<sub>2</sub> and SaO<sub>2</sub> levels in both the RG and CG group increased and the scale of improvement in RG was significantly larger than CG; differences were statistically significant (P&#x0003c;0.05). A significant difference in MVV and FEV0.3 levels were found between RG and CG after treatment; differences were statistically significant (P&#x0003c;0.05). However, no significant difference in FVC levels was found between two groups (P&#x0003e;0.05) (<xref rid="tIV-etm-0-0-4825" ref-type="table">Table IV</xref>).</p></sec><sec><title>Comparison of hospitalized time</title><p>Comparison of hospitalization time between RG and CG found that the RG group is shorter than CG group; differences were statistically significant (P&#x0003c;0.05) (<xref rid="tV-etm-0-0-4825" ref-type="table">Table V</xref>).</p></sec><sec><title>VEGF expression levels in serum</title><p>Comparing VEGF levels in the research group, control group and normal group (NG) it was found that, the RG and CG group showed higher VEGF levels than NG. Peripheral blood VEGF expression levels in RG was significantly lower than that in CG; differences were statistically significant (P&#x0003c;0.05) (<xref rid="tVI-etm-0-0-4825" ref-type="table">Table VI</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Rib fractures, pulmonary contusion and hemopneumothorax caused by severe chest trauma can easily affect a patient's respiratory function, or even lead to acute respiratory distress which will aggravate the patient's conditions. Therefore, early diagnosis and treatment are of great importance for the improvement of severe chest trauma and the patient survival. Currently, oxygen therapy is the main treatment to improve the patient respiratory distress and hypoxemia symptoms in clinical practice. However, many clinical studies have shown that mechanical ventilation treatment has a better clinical therapeutic effect for severe chest trauma patients that are accompanied by ARDS (<xref rid="b9-etm-0-0-4825" ref-type="bibr">9</xref>). Since chest trauma is often accompanied by a massive blood loss and a decrease of lung perfusion, a large amount of oxygen free radicals, leukocytic aggregation and complement activation in ischemia-reperfusion process are considered as some of the main mechanism that can cause lung injury after chest trauma (<xref rid="b5-etm-0-0-4825" ref-type="bibr">5</xref>,<xref rid="b10-etm-0-0-4825" ref-type="bibr">10</xref>).</p><p>PMN aggregation plays an important role in lung ischemia-reperfusion injury. Neutrophils accumulate in the lung and release a variety of enzymes by degranulation; a large amount of oxygen free radicals are then generated in this process which induce endothelial cell damage and strong lipid peroxidation, finally leading to lung injury (<xref rid="b11-etm-0-0-4825" ref-type="bibr">11</xref>,<xref rid="b12-etm-0-0-4825" ref-type="bibr">12</xref>). Our study found that, after treatment for 30 min, PMN value differences in peripheral blood of both research and control group are higher than before treatment. This result indicates that there was a certain degree of PMN aggregation in chest trauma patients' peripheral blood. However, after the mechanical ventilation treatment, the PMN value differences was decreased and lower than control group; differences were statistically significant (P&#x0003c;0.05). Therefore, mechanical ventilation treatment can decrease PMN aggregation and have a positive effect on improving this condition. Additionally, PVR levels of different times were significantly lower than the control group after treatment (P&#x0003c;0.05). AaDO<sub>2</sub> values in control group after treatment for 1, 3 and 6 h were all much lower than those in research group (P&#x0003c;0.05). MDA levels in research group was significantly lower than control group while the SOD and NO levels were much higher after treatment for 30 min. This indicates that the anaerobic metabolism inside of chest trauma patients' body caused a significant increase of oxidative stress levels after ischemia-reperfusion injury, thereby reducing SOD but generating a large amount of ROS in the oxidative stress process, which can cause damage to the surrounding normal tissue. A timely treatment of mechanical ventilation can improve oxidative stress.</p><p>Moreover, Ang II levels in left atrial blood were much lower than in the control group (P&#x0003c;0.05) after treatment for 30 min. Patients in this group experienced a shorter hospitalization time than control group; differences were statistically significant (P&#x0003c;0.05). Peripheral blood VEGF expression levels in RG was significantly lower than that in CG; differences were statistically significant (P&#x0003c;0.05). This result showed that the VEGF levels also have a certain effect on the lung ischemia-reperfusion process.</p><p>It has been reported that there are a variety of control mechanisms of VEGF expression levels in the lung ischemia-reperfusion process (<xref rid="b13-etm-0-0-4825" ref-type="bibr">13</xref>,<xref rid="b14-etm-0-0-4825" ref-type="bibr">14</xref>). Hypoxia and inflammation may lead to an increase in VEGF levels. Hypoxia-induced VEGF was mediated by hypoxia-inducible factor (HIF-1&#x003b1;) and combined with the core sequence of hypoxia response element in gene promoter so that it can be expressed (<xref rid="b15-etm-0-0-4825" ref-type="bibr">15</xref>). VEGF expression increases while the chest trauma is under hypoxia and ischemia conditions, but this more frequently occurs in alveolar epithelial cells. The alveolar cells damaged in the acute lung injury process can also contribute to the release of VEGF. Zhang <italic>et al</italic> found that acute inflammatory response can induce an increase in VEGF levels that are released at the early stage of acute lung injury (<xref rid="b15-etm-0-0-4825" ref-type="bibr">15</xref>&#x02013;<xref rid="b17-etm-0-0-4825" ref-type="bibr">17</xref>). Alveolar macrophages and neutrophils are a potential source of VEGF expression, while VEGF can stimulate damaged alveolar macrophages and neutrophils migrate to lung tissue. Damaged alveolar macrophages and neutrophils can produce a large amount of VEGF is related to the effects of various inflammatory cytokines like TNF-&#x003b1;, IL-6, IFN-&#x003b1;, &#x003b3; (<xref rid="b18-etm-0-0-4825" ref-type="bibr">18</xref>). Therefore, after a lung injury, the number of alveolar macrophages and neutrophils are increased as are levels of pro-inflammatory cytokines, such as VEGF expression levels. However, an early treatment of mechanical ventilation can greatly improve the patient hypoxia-ischemia status to reduce the generation of VEGF, infiltration of inflammatory cells and release of inflammatory cytokines.</p><p>In conclusion, mechanical ventilation treatment for chest trauma patients can reduce the high VEGF expression levels in serum caused by ischemic-reperfusion and has good application prospects.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-4825"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Steinle</surname><given-names>JJ</given-names></name></person-group><article-title>Compound 49b restores retinal thickness and reduces degenerate capillaries in the rat retina following ischemia/reperfusion</article-title><source>PLoS One</source><volume>11</volume><fpage>e0159532</fpage><year>2016</year><pub-id pub-id-type="doi">10.1371/journal.pone.0159532</pub-id><pub-id pub-id-type="pmid">27439004</pub-id></element-citation></ref><ref id="b2-etm-0-0-4825"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>EK</given-names></name><name><surname>Jang</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Oh</surname><given-names>MY</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Eom</surname><given-names>DW</given-names></name><name><surname>Ham</surname><given-names>JY</given-names></name><name><surname>Han</surname><given-names>DJ</given-names></name></person-group><article-title>Protective effect of polydeoxyribonucleotide against renal ischemia-reperfusion injury in mice</article-title><source>Transplant Proc</source><volume>48</volume><fpage>1251</fpage><lpage>1257</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.transproceed.2016.01.028</pub-id><pub-id pub-id-type="pmid">27320598</pub-id></element-citation></ref><ref id="b3-etm-0-0-4825"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>The effect of insulin-loaded linear poly(ethylene glycol)-brush-like poly(l-lysine) block copolymer on renal ischemia/reperfusion-induced lung injury through downregulating hypoxia-inducible factor</article-title><source>Int J Nanomed</source><volume>11</volume><fpage>1717</fpage><lpage>1730</lpage><year>2016</year></element-citation></ref><ref id="b4-etm-0-0-4825"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GH</given-names></name><name><surname>Luo</surname><given-names>B</given-names></name><name><surname>Lv</surname><given-names>YX</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>MX</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>JN</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Dual effects of VEGF-B on activating cardiomyocytes and cardiac stem cells to protect the heart against short- and long-term ischemia-reperfusion injury</article-title><source>J Transl Med</source><volume>14</volume><fpage>116</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s12967-016-0847-3</pub-id><pub-id pub-id-type="pmid">27146579</pub-id></element-citation></ref><ref id="b5-etm-0-0-4825"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>BS</given-names></name><name><surname>Ko</surname><given-names>Y</given-names></name><name><surname>Buckberg</surname><given-names>GD</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name></person-group><article-title>Studies of isolated global brain ischaemia: III. Influence of pulsatile flow during cerebral perfusion and its link to consistent full neurological recovery with controlled reperfusion following 30 min of global brain ischaemia</article-title><source>Eur J Cardiothorac Surg</source><volume>41</volume><fpage>1155</fpage><lpage>1163</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/ejcts/ezr318</pub-id><pub-id pub-id-type="pmid">22436247</pub-id></element-citation></ref><ref id="b6-etm-0-0-4825"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Auricular vagus nerve stimulation promotes functional recovery and enhances the post-ischemic angiogenic response in an ischemia/reperfusion rat model</article-title><source>Neurochem Int</source><volume>97</volume><fpage>73</fpage><lpage>82</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.neuint.2016.02.009</pub-id><pub-id pub-id-type="pmid">26964767</pub-id></element-citation></ref><ref id="b7-etm-0-0-4825"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>P</given-names></name></person-group><article-title>Monitoring of renal ischemia reperfusion injury in rabbits by ultrasonic contrast and its relationship with expression of VEGF in renal tissue</article-title><source>Asian Pac J Trop Med</source><volume>9</volume><fpage>188</fpage><lpage>192</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.apjtm.2016.01.006</pub-id><pub-id pub-id-type="pmid">26919954</pub-id></element-citation></ref><ref id="b8-etm-0-0-4825"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>CC</given-names></name><name><surname>Peng</surname><given-names>CK</given-names></name><name><surname>Tang</surname><given-names>SE</given-names></name><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Huang</surname><given-names>KL</given-names></name><name><surname>Wu</surname><given-names>CP</given-names></name></person-group><article-title>Anti-vascular endothelial growth factor antibody suppresses ERK and NF-&#x003ba;B activation in ischemia-reperfusion lung injury</article-title><source>PLoS One</source><volume>11</volume><fpage>e0159922</fpage><year>2016</year><pub-id pub-id-type="doi">10.1371/journal.pone.0159922</pub-id><pub-id pub-id-type="pmid">27513332</pub-id></element-citation></ref><ref id="b9-etm-0-0-4825"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Intraoperative mechanical ventilation strategies in patients undergoing one-lung ventilation: a meta-analysis</article-title><source>Springerplus</source><volume>5</volume><fpage>1251</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s40064-016-2867-0</pub-id><pub-id pub-id-type="pmid">27536534</pub-id></element-citation></ref><ref id="b10-etm-0-0-4825"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>C</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Inflammatory response and pneumocyte apoptosis during lung ischemia-reperfusion injury in an experimental pulmonary thromboembolism model</article-title><source>J Thromb Thrombolysis</source><volume>40</volume><fpage>42</fpage><lpage>53</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s11239-015-1182-x</pub-id><pub-id pub-id-type="pmid">25677043</pub-id></element-citation></ref><ref id="b11-etm-0-0-4825"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name><name><surname>Sydykov</surname><given-names>A</given-names></name><name><surname>Kalwa</surname><given-names>H</given-names></name><name><surname>Storch</surname><given-names>U</given-names></name><name><surname>Fuchs</surname><given-names>B</given-names></name><name><surname>Mederosy</surname><given-names>Schnitzler M</given-names></name><name><surname>Brandes</surname><given-names>RP</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name><name><surname>Meissner</surname><given-names>M</given-names></name><name><surname>Freichel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice</article-title><source>Nat Commun</source><volume>3</volume><fpage>649</fpage><year>2012</year><pub-id pub-id-type="doi">10.1038/ncomms1660</pub-id><pub-id pub-id-type="pmid">22337127</pub-id></element-citation></ref><ref id="b12-etm-0-0-4825"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancellotti</surname><given-names>P</given-names></name><name><surname>Tribouilloy</surname><given-names>C</given-names></name><name><surname>Hagendorff</surname><given-names>A</given-names></name><name><surname>Popescu</surname><given-names>BA</given-names></name><name><surname>Edvardsen</surname><given-names>T</given-names></name><name><surname>Pierard</surname><given-names>LA</given-names></name><name><surname>Badano</surname><given-names>L</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name></person-group><article-title>Scientific Document Committee of the European Association of Cardiovascular Imaging: Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging</article-title><source>Eur Heart J Cardiovasc Imaging</source><volume>14</volume><fpage>611</fpage><lpage>644</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/ehjci/jet105</pub-id><pub-id pub-id-type="pmid">23733442</pub-id></element-citation></ref><ref id="b13-etm-0-0-4825"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marti</surname><given-names>HH</given-names></name><name><surname>Risau</surname><given-names>W</given-names></name></person-group><article-title>Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors</article-title><source>Proc Natl Acad Sci USA</source><volume>95</volume><fpage>15809</fpage><lpage>15814</lpage><year>1998</year><pub-id pub-id-type="doi">10.1073/pnas.95.26.15809</pub-id><pub-id pub-id-type="pmid">9861052</pub-id></element-citation></ref><ref id="b14-etm-0-0-4825"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Bae</surname><given-names>SH</given-names></name><name><surname>Jeong</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name></person-group><article-title>Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions</article-title><source>Exp Mol Med</source><volume>36</volume><fpage>1</fpage><lpage>12</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/emm.2004.1</pub-id><pub-id pub-id-type="pmid">15031665</pub-id></element-citation></ref><ref id="b15-etm-0-0-4825"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XD</given-names></name><name><surname>Hai</surname><given-names>CX</given-names></name><name><surname>Cai</surname><given-names>FL</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Qin</surname><given-names>XJ</given-names></name><name><surname>Feng</surname><given-names>AJ</given-names></name></person-group><article-title>Time course for expression of VEGF and its receptor and regulator levels of contraction and relaxation in increased vascular permeability of lung induced by phosgene</article-title><source>Inhal Toxicol</source><volume>20</volume><fpage>805</fpage><lpage>812</lpage><year>2008</year><pub-id pub-id-type="doi">10.1080/08958370802015091</pub-id><pub-id pub-id-type="pmid">18645720</pub-id></element-citation></ref><ref id="b16-etm-0-0-4825"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thickett</surname><given-names>DR</given-names></name><name><surname>Armstrong</surname><given-names>L</given-names></name><name><surname>Christie</surname><given-names>SJ</given-names></name><name><surname>Millar</surname><given-names>AB</given-names></name></person-group><article-title>Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><volume>164</volume><fpage>1601</fpage><lpage>1605</lpage><year>2001</year><pub-id pub-id-type="doi">10.1164/ajrccm.164.9.2011071</pub-id><pub-id pub-id-type="pmid">11719296</pub-id></element-citation></ref><ref id="b17-etm-0-0-4825"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>NJ</given-names></name><name><surname>Myers</surname><given-names>CR</given-names></name><name><surname>Watson</surname><given-names>CJ</given-names></name><name><surname>Bottomley</surname><given-names>MJ</given-names></name><name><surname>Brenchley</surname><given-names>PE</given-names></name></person-group><article-title>Activated human neutrophils express vascular endothelial growth factor (VEGF)</article-title><source>Cytokine</source><volume>10</volume><fpage>254</fpage><lpage>257</lpage><year>1998</year><pub-id pub-id-type="doi">10.1006/cyto.1997.0297</pub-id><pub-id pub-id-type="pmid">9617569</pub-id></element-citation></ref><ref id="b18-etm-0-0-4825"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Nahari</surname><given-names>D</given-names></name><name><surname>Cerem</surname><given-names>LW</given-names></name><name><surname>Neufeld</surname><given-names>G</given-names></name><name><surname>Levi</surname><given-names>BZ</given-names></name></person-group><article-title>Interleukin 6 induces the expression of vascular endothelial growth factor</article-title><source>J Biol Chem</source><volume>271</volume><fpage>736</fpage><lpage>741</lpage><year>1996</year><pub-id pub-id-type="doi">10.1074/jbc.271.2.736</pub-id><pub-id pub-id-type="pmid">8557680</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-0-0-4825" orientation="portrait" position="float"><label>Table I.</label><caption><p>Clinical settings of investigated patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gender (male/female)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Age (years)</th><th align="center" valign="bottom" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">NYHA (II/III)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Bleeding volume</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment time (min)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">19/16</td><td align="center" valign="top" rowspan="1" colspan="1">52.4&#x000b1;12.3</td><td align="center" valign="top" rowspan="1" colspan="1">23.3&#x000b1;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">29/31</td><td align="center" valign="top" rowspan="1" colspan="1">172.3&#x000b1;12.6</td><td align="center" valign="top" rowspan="1" colspan="1">51.2&#x000b1;12.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">20/14</td><td align="center" valign="top" rowspan="1" colspan="1">55.6&#x000b1;7.2</td><td align="center" valign="top" rowspan="1" colspan="1">22.4&#x000b1;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">28/32</td><td align="center" valign="top" rowspan="1" colspan="1">187.8&#x000b1;28.5</td><td align="center" valign="top" rowspan="1" colspan="1">53.2&#x000b1;22.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F/&#x003c7;<sup>2</sup> value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.82</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-4825"><p>RG, research group; CG, control group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-0-0-4825" orientation="portrait" position="float"><label>Table II.</label><caption><p>PVR comparation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="4" rowspan="1">After treatment</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="4" rowspan="1"><hr/></th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">3 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">6 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">12 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">F-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">331.6&#x000b1;25.7</td><td align="center" valign="top" rowspan="1" colspan="1">231.7&#x000b1;45.3</td><td align="center" valign="top" rowspan="1" colspan="1">182.7&#x000b1;42.8</td><td align="center" valign="top" rowspan="1" colspan="1">92.3&#x000b1;29.6</td><td align="center" valign="top" rowspan="1" colspan="1">122.4&#x000b1;23.6</td><td align="center" valign="top" rowspan="1" colspan="1">31.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">348.9&#x000b1;12.6</td><td align="center" valign="top" rowspan="1" colspan="1">252.6&#x000b1;23.8</td><td align="center" valign="top" rowspan="1" colspan="1">184.5&#x000b1;33.6</td><td align="center" valign="top" rowspan="1" colspan="1">93.2&#x000b1;22.8</td><td align="center" valign="top" rowspan="1" colspan="1">121.4&#x000b1;22.5</td><td align="center" valign="top" rowspan="1" colspan="1">48.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">2.57</td><td align="center" valign="top" rowspan="1" colspan="1">14.7</td><td align="center" valign="top" rowspan="1" colspan="1">21.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-etm-0-0-4825"><p>Pulmonary vascular resistance; RG, research group; CG, control group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-0-0-4825" orientation="portrait" position="float"><label>Table III.</label><caption><p>Left atrial ejection SOD, MDA, Ang II and NO level comparation 30 min before and after treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">After treatment 1/2 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">F-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SOD (NU/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">131.6&#x000b1;15.7</td><td align="center" valign="top" rowspan="1" colspan="1">171.7&#x000b1;49.3</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">138.9&#x000b1;12.8</td><td align="center" valign="top" rowspan="1" colspan="1">172.6&#x000b1;22.8</td><td align="center" valign="top" rowspan="1" colspan="1">58.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MDA (nmol/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">2.28&#x000b1;0.14</td><td align="center" valign="top" rowspan="1" colspan="1">3.38&#x000b1;1.02</td><td align="center" valign="top" rowspan="1" colspan="1">4.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.017</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">2.39&#x000b1;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">3.25&#x000b1;0.97</td><td align="center" valign="top" rowspan="1" colspan="1">5.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">12.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.66</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ang II (pg/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">77.4&#x000b1;12.81</td><td align="center" valign="top" rowspan="1" colspan="1">168.4&#x000b1;10.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.38</td><td align="center" valign="top" rowspan="1" colspan="1">0.021</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">80.4&#x000b1;13.9</td><td align="center" valign="top" rowspan="1" colspan="1">166.4&#x000b1;12.8</td><td align="center" valign="top" rowspan="1" colspan="1">1.98</td><td align="center" valign="top" rowspan="1" colspan="1">0.024</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">21.4</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NO (&#x000b5;mol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">38.4&#x000b1;11.3</td><td align="center" valign="top" rowspan="1" colspan="1">78.2&#x000b1;22.4</td><td align="center" valign="top" rowspan="1" colspan="1">10.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">35.7&#x000b1;14.8</td><td align="center" valign="top" rowspan="1" colspan="1">74.4&#x000b1;23.5</td><td align="center" valign="top" rowspan="1" colspan="1">11.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.014</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.26</td><td align="center" valign="top" rowspan="1" colspan="1">22.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.73</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PMN</td><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">0.28&#x000b1;0.56</td><td align="center" valign="top" rowspan="1" colspan="1">3.72&#x000b1;1.15</td><td align="center" valign="top" rowspan="1" colspan="1">7.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">0.35&#x000b1;0.76</td><td align="center" valign="top" rowspan="1" colspan="1">2.41&#x000b1;1.73</td><td align="center" valign="top" rowspan="1" colspan="1">6.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.032</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="center" valign="top" rowspan="1" colspan="1">9.94</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-etm-0-0-4825"><p>SOD, superoxide dismutase; MDA, malondialdehyde; RG, research group; CG, control group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-0-0-4825" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Blood gas index and lung function comparation between before treatment and after treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">N</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">PaCO<sub>2</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">PaO<sub>2</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">SaO<sub>2</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">MVV</th><th align="center" valign="bottom" rowspan="1" colspan="1">FVC</th><th align="center" valign="bottom" rowspan="1" colspan="1">FEV0.3</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="left" valign="top" rowspan="1" colspan="1">Before</td><td align="center" valign="top" rowspan="1" colspan="1">6.96&#x000b1;0.31</td><td align="center" valign="top" rowspan="1" colspan="1">7.21&#x000b1;0.63</td><td align="center" valign="top" rowspan="1" colspan="1">0.83&#x000b1;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">86.52&#x000b1;18.31</td><td align="center" valign="top" rowspan="1" colspan="1">5.44&#x000b1;1.14</td><td align="center" valign="top" rowspan="1" colspan="1">2.59&#x000b1;0.45</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="center" valign="top" rowspan="1" colspan="1">4.38&#x000b1;0.36</td><td align="center" valign="top" rowspan="1" colspan="1">8.94&#x000b1;1.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.99&#x000b1;0.07</td><td align="center" valign="top" rowspan="1" colspan="1">151.36&#x000b1;36.21<sup><xref rid="tfn5-etm-0-0-4825" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">5.53&#x000b1;1.02</td><td align="center" valign="top" rowspan="1" colspan="1">3.61&#x000b1;0.28<sup><xref rid="tfn5-etm-0-0-4825" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.93</td><td align="center" valign="top" rowspan="1" colspan="1">11.24</td><td align="center" valign="top" rowspan="1" colspan="1">13.25</td><td align="center" valign="top" rowspan="1" colspan="1">12.82</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td><td align="center" valign="top" rowspan="1" colspan="1">10.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="left" valign="top" rowspan="1" colspan="1">Before</td><td align="center" valign="top" rowspan="1" colspan="1">6.91&#x000b1;0.36</td><td align="center" valign="top" rowspan="1" colspan="1">7.25&#x000b1;0.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.84&#x000b1;0.06</td><td align="center" valign="top" rowspan="1" colspan="1">87.32&#x000b1;29.32</td><td align="center" valign="top" rowspan="1" colspan="1">5.61&#x000b1;0.78</td><td align="center" valign="top" rowspan="1" colspan="1">2.67&#x000b1;0.43</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="center" valign="top" rowspan="1" colspan="1">5.94&#x000b1;0.71</td><td align="center" valign="top" rowspan="1" colspan="1">7.35&#x000b1;1.36</td><td align="center" valign="top" rowspan="1" colspan="1">0.88&#x000b1;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">88.64&#x000b1;28.62</td><td align="center" valign="top" rowspan="1" colspan="1">5.51&#x000b1;1.06</td><td align="center" valign="top" rowspan="1" colspan="1">2.54&#x000b1;0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.63</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-etm-0-0-4825"><p>Comparing with CG</p></fn><fn id="tfn5-etm-0-0-4825"><label>a</label><p>P&#x0003c;0.05. RG, research group; CG, control group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tV-etm-0-0-4825" orientation="portrait" position="float"><label>Table V.</label><caption><p>Comparation of hospitalized time.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hospitalized time (days)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">7.87&#x000b1;1.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">9.36&#x000b1;2.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">10.92</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-etm-0-0-4825"><p>RG, research group; CG, control group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tVI-etm-0-0-4825" orientation="portrait" position="float"><label>Table VI.</label><caption><p>VEGF expression level in serum (ng/&#x000b5;l).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">After treatment 1/2 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">T-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">18.28&#x000b1;8.32</td><td align="center" valign="top" rowspan="1" colspan="1">4.58&#x000b1;2.19</td><td align="center" valign="top" rowspan="1" colspan="1">10.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">19.21&#x000b1;4.39</td><td align="center" valign="top" rowspan="1" colspan="1">18.38&#x000b1;3.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NG</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">3.83&#x000b1;1.28</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">12.83</td><td align="center" valign="top" rowspan="1" colspan="1">14.22</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn7-etm-0-0-4825"><p>VEGF, vascular endothelial growth factor; RG, research group; CG, control group.</p></fn></table-wrap-foot></table-wrap></floats-group></article>